Replies to post #346990 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Oncovir is the commercial company that is providing the poly-ICLC for this trial. The autologous tumor lysate (ATL) - dendritic cell (DC) vaccine is being made in UCLA’s laboratory.

NWBio is not producing DCVax-L for this trial, through its CMOs (Cognate & Advent Bioservices). DCVax-L is the trademarked name for NWBio’s autologous tumor lysate (ATL) dendritic cell (DC) vaccine. ATL-DC is the generic name for DCVax-L.

I personally believe that UCLA, Merck & NWBio want to obscure & downplay the connections between the 3 entities, and hide in plain view, the combination trial for DCVax-L & Keytruda. This allows NWBio to focus on releasing TLD, and prevent Merck & NWBio from having to answer questions about the interest they may have in each other.

[ATLnsider]

Also, nsgmd5, if you can read between the lines, and you know where to look, you will see the obvious connections between: UCLA, NWBio, Merck, DCVax & Keytruda. Take a look at the ATL-DC + Keytruda trial Sponsors & Collaborators on the clinical trials.org site link below:

UCLA - Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme Corp.
Phase One Foundation
Oncovir, Inc

https://clinicaltrials.gov/ct2/show/NCT04201873

Then take a look at who is the Phase One Foundation, and the money ($400,000) they gave to UCLA to conduct this study:

https://www.phaseonefoundation.org/latest-news/cancer-researchers-develop-immunebased-therapies-for-deadly-brain-tumors

Then, go to the above link and look for this paragragraph:

The funding will help open a clinical trial testing a combination treatment strategy using checkpoint inhibitors in conjunction with a personalized dendritic cell vaccine, which was developed by Liau at UCLA

Then, touch the blue link in this paragraph, it says: “was developed by Liau”. This blue link will take you to this page:

https://newsroom.ucla.edu/releases/personalized-vaccine-increase-long-term-survival-glioblastoma

This page clearly shows you that the ATL-DC vaccine developed by Dr. Linda Liau is DCVax-L. It says the following:

The vaccine, known as DCVax-L, uses a person’s own white blood cells to help activate the immune system to fight cancer